$6.21
+0.02
(+0.32%)▲
1.37%
Downside
Day's Volatility :3.16%
Upside
1.82%
36.23%
Downside
52 Weeks Volatility :65.45%
Upside
45.81%
Period | Bausch Health Companies Inc | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | -0.96% | 5.1% | 0.0% |
6 Months | -33.08% | 4.9% | 0.0% |
1 Year | -26.25% | 16.6% | 0.0% |
3 Years | -78.75% | 13.2% | -22.3% |
Market Capitalization | 2.3B |
Book Value | - $3.2 |
Earnings Per Share (EPS) | -1.29 |
PEG Ratio | 0.63 |
Wall Street Target Price | 7.64 |
Profit Margin | -5.12% |
Operating Margin TTM | 17.6% |
Return On Assets TTM | 4.16% |
Return On Equity TTM | -2304.54% |
Revenue TTM | 9.2B |
Revenue Per Share TTM | 25.1 |
Quarterly Revenue Growth YOY | 10.9% |
Gross Profit TTM | 5.8B |
EBITDA | 3.0B |
Diluted Eps TTM | -1.29 |
Quarterly Earnings Growth YOY | -0.61 |
EPS Estimate Current Year | 3.61 |
EPS Estimate Next Year | 4.16 |
EPS Estimate Current Quarter | 0.88 |
EPS Estimate Next Quarter | 1.04 |
What analysts predicted
Upside of 23.03%
FY18 | Y/Y Change | |
---|---|---|
Revenue | 8.4B | ↓ 3.94% |
Net Income | -4.1B | ↓ 272.55% |
Net Profit Margin | -49.5% | ↓ 77.06% |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 8.6B | ↑ 2.64% |
Net Income | -1.8B | ↓ 57.02% |
Net Profit Margin | -20.73% | ↑ 28.77% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 8.0B | ↓ 6.67% |
Net Income | -559.0M | ↓ 68.65% |
Net Profit Margin | -6.96% | ↑ 13.77% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 8.4B | ↑ 5.07% |
Net Income | -937.0M | ↑ 67.62% |
Net Profit Margin | -11.11% | ↓ 4.15% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 8.1B | ↓ 3.68% |
Net Income | -212.0M | ↓ 77.37% |
Net Profit Margin | -2.61% | ↑ 8.5% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 8.8B | ↑ 7.79% |
Net Income | -592.0M | ↑ 179.25% |
Net Profit Margin | -6.76% | ↓ 4.15% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 1.9B | ↓ 11.35% |
Net Income | -209.0M | ↓ 49.02% |
Net Profit Margin | -10.75% | ↑ 7.95% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 2.2B | ↑ 11.47% |
Net Income | 26.0M | ↓ 112.44% |
Net Profit Margin | 1.2% | ↑ 11.95% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 2.2B | ↑ 3.28% |
Net Income | -378.0M | ↓ 1553.85% |
Net Profit Margin | -16.89% | ↓ 18.09% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | 2.4B | ↑ 7.6% |
Net Income | 395.0M | ↓ 204.5% |
Net Profit Margin | 16.4% | ↑ 33.29% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Revenue | 2.1B | ↓ 10.99% |
Net Income | -63.7M | ↓ 116.13% |
Net Profit Margin | -2.97% | ↓ 19.37% |
Q2 FY24 | Q/Q Change | |
---|---|---|
Revenue | 2.4B | ↑ 12.09% |
Net Income | 10.0M | ↓ 115.7% |
Net Profit Margin | 0.42% | ↑ 3.39% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 27.4B | ↓ 26.8% |
Total Liabilities | 24.6B | ↓ 21.93% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 33.9B | ↑ 23.38% |
Total Liabilities | 32.7B | ↑ 32.86% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 31.2B | ↓ 7.87% |
Total Liabilities | 30.6B | ↓ 6.52% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 29.2B | ↓ 6.4% |
Total Liabilities | 29.2B | ↓ 4.44% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 25.7B | ↓ 12.04% |
Total Liabilities | 25.4B | ↓ 13.03% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 27.4B | ↑ 6.48% |
Total Liabilities | 27.4B | ↑ 7.89% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 25.4B | ↓ 0.94% |
Total Liabilities | 25.3B | ↓ 0.5% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 33.8B | ↑ 32.82% |
Total Liabilities | 33.4B | ↑ 32.16% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 27.1B | ↓ 19.92% |
Total Liabilities | 27.3B | ↓ 18.36% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 27.4B | ↑ 1.06% |
Total Liabilities | 27.4B | ↑ 0.49% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 26.9B | ↓ 1.7% |
Total Liabilities | 27.1B | ↓ 1.36% |
Q2 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 26.5B | ↓ 1.47% |
Total Liabilities | 26.7B | ↓ 1.26% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 1.5B | ↓ 34.45% |
Investing Cash Flow | -196.0M | ↓ 106.79% |
Financing Cash Flow | -1.4B | ↓ 72.74% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 1.5B | ↑ 0.0% |
Investing Cash Flow | -419.0M | ↑ 113.78% |
Financing Cash Flow | 1.4B | ↓ 206.65% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 1.1B | ↓ 25.98% |
Investing Cash Flow | -261.0M | ↓ 37.71% |
Financing Cash Flow | -2.3B | ↓ 258.97% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 1.4B | ↑ 28.35% |
Investing Cash Flow | 409.0M | ↓ 256.7% |
Financing Cash Flow | -1.5B | ↓ 34.05% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -728.0M | ↓ 151.05% |
Investing Cash Flow | -303.0M | ↓ 174.08% |
Financing Cash Flow | -474.0M | ↓ 68.67% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 154.0M | ↓ 67.58% |
Investing Cash Flow | -78.0M | ↓ 74.26% |
Financing Cash Flow | -142.0M | ↓ 48.55% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 268.8M | ↑ 74.53% |
Investing Cash Flow | -30.0M | ↓ 61.54% |
Financing Cash Flow | -120.0M | ↓ 15.49% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 282.0M | ↑ 4.92% |
Investing Cash Flow | -2.0B | ↑ 6556.67% |
Financing Cash Flow | 1.8B | ↓ 1613.33% |
Sell
Neutral
Buy
Bausch Health Companies Inc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
![]() Bausch Health Companies Inc | 18.97% | -33.08% | -26.25% | -78.75% | -71.89% |
![]() Neurocrine Biosciences Inc. | -16.62% | -11.2% | 10.78% | 28.21% | 20.17% |
![]() Haleon Plc Spon Ads | 7.49% | 20.82% | 28.48% | 39.41% | 39.41% |
![]() Zoetis Inc. | 2.41% | 4.25% | 0.77% | -8.94% | 49.4% |
![]() Viatris Inc. | -0.79% | -8.6% | 12.7% | -23.12% | -31.03% |
![]() Catalent, Inc. | 0.82% | 6.48% | 22.57% | -57.47% | 16.16% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
![]() Bausch Health Companies Inc | 71.75 | NA | 0.63 | 3.61 | -23.05 | 0.04 | NA | -3.2 |
![]() Neurocrine Biosciences Inc. | 36.53 | 36.53 | 0.27 | 4.57 | 0.16 | 0.12 | NA | 24.87 |
![]() Haleon Plc Spon Ads | 33.32 | 33.32 | 1.47 | 0.39 | 0.07 | 0.04 | 0.02 | 1.82 |
![]() Zoetis Inc. | 36.6 | 36.6 | 2.61 | 5.82 | 0.49 | 0.14 | 0.01 | 10.94 |
![]() Viatris Inc. | 224.4 | NA | 0.07 | 2.68 | -0.03 | 0.03 | 0.04 | 16.36 |
![]() Catalent, Inc. | 211.02 | NA | 2.87 | 0.2 | -0.25 | 0.0 | NA | 19.91 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
![]() Bausch Health Companies Inc | Hold | $2.3B | -71.89% | 71.75 | -5.12% |
![]() Neurocrine Biosciences Inc. | Buy | $12.2B | 20.17% | 36.53 | 16.0% |
![]() Haleon Plc Spon Ads | Buy | $47.1B | 39.41% | 33.32 | 9.66% |
![]() Zoetis Inc. | Buy | $85.7B | 49.4% | 36.6 | 26.29% |
![]() Viatris Inc. | Hold | $13.5B | -31.03% | 224.4 | -4.24% |
![]() Catalent, Inc. | Hold | $10.9B | 16.16% | 211.02 | -23.81% |
Insights on Bausch Health Companies Inc
Revenue is up for the last 2 quarters, 2.14B → 2.40B (in $), with an average increase of 10.8% per quarter
Netprofit is up for the last 2 quarters, -63.71M → 10.0M (in $), with an average increase of 737.1% per quarter
In the last 1 year, Haleon Plc Spon Ads has given 28.5% return, outperforming this stock by 54.7%
ICAHN CARL C
Paulson & Company Inc
Goldentree Asset Management LP
Nomura Holdings Inc
HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND
Hudson Bay Capital Management LP
bausch health companies inc. (nyse/tsx: bhc) is a global company that develops, manufactures and markets a range of pharmaceutical, medical device and over-the-counter products, primarily in the therapeutic areas of eye health, gastroenterology and dermatology. we are delivering on our commitments as we build an innovative company dedicated to advancing global health. our approximately 22,000 employees are united around our mission of improving people’s lives with our health care products, and we manufacture and market health care products directly or indirectly in approximately 100 countries.five pillars, or guiding principles, represent the foundation on which we are realizing our mission as an organization: people, quality health care outcomes, customer focus, innovation and efficiency. more information can be found at www.bauschhealth.com.###
Organization | Bausch Health Companies Inc |
Employees | 20270 |
CEO | Mr. Thomas J. Appio |
Industry | Health Technology |
Assetmark Financial Holdings Inc
$6.21
+0.32%
Fidelity Msci Health Care Etf
$6.21
+0.32%
Texas Capital Bancshares Inc.
$6.21
+0.32%
Primerica, Inc.
$6.21
+0.32%
Thor Industries Inc.
$6.21
+0.32%
Qifu Technology Inc
$6.21
+0.32%
Crinetics Pharmaceuticals Inc
$6.21
+0.32%
Hercules Capital Inc
$6.21
+0.32%
Janus Henderson Mortgage-backed Securities Etf
$6.21
+0.32%